Juvenile xanthogranuloma manifesting with LCH-associated neurodegenerative disease-like radiological findings.
histiocytic disorders
juvenile xanthogranuloma
neurodegenerative diseases
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
28 Apr 2024
28 Apr 2024
Historique:
revised:
05
04
2024
received:
19
02
2024
accepted:
12
04
2024
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
29
4
2024
Statut:
aheadofprint
Résumé
Here, we describe two patients with juvenile xanthogranuloma (JXG) manifesting with Langerhans cell histiocytosis (LCH)-associated neurodegenerative disease (ND)-like radiological findings. One patient showed typical radiological abnormalities at onset, which worsened with progressing central nervous system symptoms 7 years after LCH-oriented chemotherapy. Another showed spontaneous regression of clinical symptoms, with a transient radiological change 1 year after salvage chemotherapy for recurrence of JXG. These data regarding JXG-associated ND will facilitate future investigation of the disease, as well as development of therapeutic interventions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31043Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Durham BH. Molecular characterization of the histiocytoses: neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol. 2019;86:62‐76.
Maeda N, Morimoto A, Shioda Y, et al. Long‐term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan. Pediatr Blood Cancer. 2020;67:e28381.
Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage‐dendritic cell lineages. Blood. 2016;127:2672‐2681.
Cohen Aubart F, Idbaih A, Emile JF, et al. Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro Oncol. 2021;23:1433‐1446.
Héritier S, Barkaoui MA, Miron J, et al. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol. 2018;183:608‐617.
Morimoto A, Shioda Y, Imamura T, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group‐02 Protocol study. Int J Hematol. 2016;104:99‐109.
Kinehara T, Umeda K, Saida S, et al. Disseminated xanthogranuloma with multiple lesions of the central nervous system. Jpn J Pediatr Hematol Oncol. 2016;53:152‐157.
Kudo K, Toki T, Kanezaki R, et al. BRAF V600E‐positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis. Haematologica. 2022;107:1719‐1725.
Shimizu S, Sakamoto K, Kudo K, et al. Detection of BRAF V600E mutation in radiological Langerhans cell histiocytosis‐associated neurodegenerative disease using droplet digital PCR analysis. Int J Hematol. 2023;118:119‐124.
Picarsic J, Pysher T, Zhou H, et al. BRAF V600E mutation in juvenile xanthogranuloma family neoplasms of the central nervous system (CNS‐JXG): a revised diagnostic algorithm to include pediatric Erdheim–Chester disease. Acta Neuropathol Commun. 2019;7:168.
Kim S, Lee M, Shin HJ, et al. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim–Chester disease in a pediatric patient: a case report. Childs Nerv Syst. 2016;32:893‐896.
Martin JM, Jordá E, Martín‐Gorgojo A, et al. Histiocytosis with mixed cell populations. J Cutan Pathol. 2016;43:456‐460.
Yeh EA, Greenberg J, Abla O, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr Blood Cancer. 2018;65(1):e26784.
Mass E, Jacome‐Galarza CE, Blank T, et al. A somatic mutation in erythron‐myeloid progenitors causes neurogenerative disease. Nature. 2017;549:389‐393.
Wilk CM, Cathomas F, Török O, et al. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023;56:2790‐2802.e6.
Imashuku S, Fujita N, Shioda Y, et al. Follow‐up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)‐related neurodegenerative CNS disease. Int J Hematol. 2015;101:191‐197.
Allen CE, Flores R, Rauch R, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010;54:416‐423.
Ehrhardt MJ, Karst J, Donohoue PA, et al. Recognition and treatment of concurrent active and neurodegenerative Langerhans cell histiocytosis: a case report. J Pediatr Hematol Oncol. 2015;37:e37‐e40.
McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH‐associated neurodegeneration and mass lesion. Cancer. 2018;124:2607‐2620.